I must say I haven't come across a biotech start-up that has lower MC than cash balance and their quarterly expense that doesn't include R&D is only $1.4M per quarter and around $6M per quarter on R&D, last year BOT spent $16M on R&D and they received around 50% which is the normal rate on R&D rebate so I can't see them running out of cash for a few years....they will need to prove their medical product works in clinical trial settings though for the R&D expenditure to significantly decrease.
I must say I haven't come across a biotech start-up that has...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.025(7.25%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 32.0¢ | $1.732M | 5.231M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 413440 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 46819 | 2 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |